Extracellular purines, purinergic receptors and tumor growth

• Published in: Oncogene Vol. 36; no. 3; pp. 293 - 303
• Main Authors: Di Virgilio, F, Adinolfi, E
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 19.01.2017
• Subjects: Adenosine; Analysis; Animals; Cellular biology; Dosage and administration; Homeostasis; Humans; Mice; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; Nucleosides; Physiological aspects; Purines; Purines - metabolism; Receptors, Purinergic - metabolism; Review; Signal Transduction; Studies; Transforming growth factors; Tumor Microenvironment; Tumors
• ISSN: 0950-9232; 1476-5594
• DOI: 10.1038/onc.2016.206

Virtually, all tumor cells as well as all immune cells express plasma membrane receptors for extracellular nucleosides (adenosine) and nucleotides (ATP, ADP, UTP, UDP and sugar UDP). The tumor microenvironment is characterized by an unusually high concentration of ATP and adenosine. Adenosine is a major determinant of the immunosuppressive tumor milieu. Sequential hydrolysis of extracellular ATP catalyzed by CD39 and CD73 is the main pathway for the generation of adenosine in the tumor interstitium. Extracellular ATP and adenosine mold both host and tumor responses. Depending on the specific receptor activated, extracellular purines mediate immunosuppression or immunostimulation on the host side, and growth stimulation or cytotoxicity on the tumor side. Recent progress in this field is providing the key to decode this complex scenario and to lay the basis to harness the potential benefits for therapy. Preclinical data show that targeting the adenosine-generating pathway (that is, CD73) or adenosinergic receptors (that is, A2A) relieves immunosuppresion and potently inhibits tumor growth. On the other hand, growth of experimental tumors is strongly inhibited by targeting the P2X7 ATP-selective receptor of cancer and immune cells. This review summarizes the recent data on the role played by extracellular purines (purinergic signaling) in host-tumor interaction and highlights novel therapeutic options stemming from recent advances in this field.